Carriers of pathogenic variants (PV) in BRCA1 (OMIM 113705) and BRCA2 (OMIM 600185) are at increased risk of breast cancer (BC) and ovarian cancer (OC), with absolute risks of 61% to 72% and 17% to 48%, respectively, up to age 80 years.1,2 Current Canadian national and international guidelines recommend women undertake BRCA1/BRCA2 genetic testing if they fulfil established clinical or family history (FH) criteria. The gene discussed is BRCA2; the disease is ovarian cancer.